# ClinicalTrials.gov record NCT06388642

> PeptideScanner retained ClinicalTrials.gov record NCT06388642 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was afamelanotide.

- Evidence object: `story:clinicaltrials-gov-nct06388642-afamelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06388642-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06388642-afamelanotide-v1.json
- Content SHA-256: `bd1aa37e6dbb0f7e0ac0b1549844512a34e2fcb965fef0982fc5691f3e3a01cd`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06388642 ([`ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb`](#source-ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06388642 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb`](#source-ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06388642 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb`](#source-ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb`](#source-ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb))

## Sources

<a id="source-ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb"></a>
- **ClinicalTrials.gov record NCT06388642 · retained source version 2026-07-27:f06c4c6dcffbc5ad15069174f309dc3ab78a1962e3d85f6f8b9bb7694ec86c35** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06388642) (`ctg-observation-nct06388642-2026-07-27-f06c4c6dcffb`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06388642." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06388642-afamelanotide-v1.json SHA-256: bd1aa37e6dbb0f7e0ac0b1549844512a34e2fcb965fef0982fc5691f3e3a01cd.